ReviewClinical microbiology reviews2004
Diagnosis and assessment of trachoma.
Review in Clinical microbiology reviews, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
91 citing papers in PubMed, 2 syntheses or guidelines pooled it, 179 citations in OpenAlex.
- Stopping azithromycin mass drug administration for trachoma: A systematic review.PLoS neglected tropical diseases · 2021Pooled it
- Epidemiology and control of trachoma: systematic review.Tropical medicine & international health : TM & IH · 2010Pooled it
- Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions.Investigative ophthalmology & visual science · 2012Trial
- How reliable are tests for trachoma?--a latent class approach.Investigative ophthalmology & visual science · 2011Trial
- Impact of two rounds of azithromycin mass drug administration on active trachoma and ocular Chlamydia trachomatis infection in Naoero.PLoS neglected tropical diseases · 2026Article
- Dynamics of trachoma infection in West Africa revealed by a hidden state model.PLoS computational biology · 2026Article
- Population-based concordance ofMicrobiology spectrum · 2025Article
- The prevalence of trachoma, ocular Chlamydia trachomatis infection and anti-Pgp3 antibodies in Choiseul Province, Solomon Islands.PLoS neglected tropical diseases · 2025Article
- Cost-effectiveness of adding measurement of Chlamydia trachomatis infection and serology to trachoma prevalence surveys in Tanzania and Mozambique.PLoS neglected tropical diseases · 2025Article
- Trachoma.Lancet (London, England) · 2025Review
- Validation of a New Duplex Real-Time Polymerase Chain Reaction forDiagnostics (Basel, Switzerland) · 2024Article
- A suitable and efficient optimization system for the culture of Chlamydia trachomatis in adult inclusion conjunctivitis.Pathogens and disease · 2024Article
- Prevalence of Trachoma following Implementation of the SAFE Strategy in Three Local Government Areas of Taraba State, North Eastern Nigeria.Ophthalmic epidemiology · 2023Article
- Prevalence of active trachoma infection and associated factors post-war resettled population in raya kobo districts, North East Ethiopia: A community-based cross-sectional study in 2022.Health science reports · 2023Article
- Assessment of the status of improved F&E trachoma control practices among children of agro-pastoralists in Southern Ethiopia: a mixed design survey using theory of triadic influences.BMC public health · 2023Article
- Exploring multi-level risk factors and post-war burdens of trachomatous trichiasis among displaced population in Raya Kobo districts, implication for urgent action.International journal of ophthalmology · 2023Article
- Where should we offer mass drug administration for trachoma?The Medical journal of Australia · 2022Article
- Associated factors of the co-occurrence of trachoma and soil-transmitted helminthiases in children 1 to 9 years old in rural communities of the Amazon basin in Loreto Department, Peru: Results from a population-based survey.PLoS neglected tropical diseases · 2022Article
- Trachoma.Nature reviews. Disease primers · 2022Review
- Model-based geostatistics enables more precise estimates of neglected tropical-disease prevalence in elimination settings: mapping trachoma prevalence in Ethiopia.International journal of epidemiology · 2022Article
31 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 3 countries.
Funding
Abstract
Trachoma is caused by Chlamydia trachomatis. Clinical grading with the WHO simplified system can be highly repeatable provided graders are adequately trained and standardized. At the community level, rapid assessments are useful for confirming the absence of trachoma but do not determine the magnitude of the problem in communities where trachoma is present. New rapid assessment protocols incorporating techniques for obtaining representative population samples (without census preparation) may give better estimates of the prevalence of clinical trachoma. Clinical findings do not necessarily indicate the presence or absence of C. trachomatis infection, particularly as disease prevalence falls. The prevalence of ocular C. trachomatis infection (at the community level) is important because it is infection that is targeted when antibiotics are distributed in trachoma control campaigns. Methods to estimate infection prevalence are required. While culture is a sensitive test for the presence of viable organisms and nucleic acid amplification tests are sensitive and specific tools for the presence of chlamydial nucleic acids, the commercial assays presently available are all too expensive, too complex, or too unreliable for use in national programs. There is an urgent need for a rapid, reliable test for C. trachomatis to assist in measuring progress towards the elimination of trachoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.